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Abstract. Compatible with the epidemiology and natural 
history of cervical cancer and with experimental findings that 
HPV-immortalized nontumorigenic cells are similar to 
cervical carcinoma cells, in terms of the quantity and type of 
viral RNA expressed, it is believed that additional cellular 
genetic events are necessary for tumorigenic conversion. In 
the current study we detected codon 12 point mutations of 
the K-ras oncogene with an incidence of 28.2% in malignant 
lesions of the cervix, as well as HPV 18 at a higher rate than 
HPV16 (30.2% vs 27.9%) in genital lesions, by PCR and 
RFLP analysis. Codon 12 point mutations of K-, H- and N-
ras were also found in benign lesions of the cervix, in 
endometrial and in ovarian carcinomas, although at a lower 
frequency. It is suggested that the mutationally activated ras 
oncogenes cooperate with HPV in the early stages of 
carcinogenesis of the human female reproductive tract. 
Introduction 
Human papilloma viruses (HPVs) are strongly implicated in 
the genesis of human cervical carcinoma, anal squamous cell 
carcinoma, squamous cell carcinoma of the skin and isolated 
cases of squamous cell carcinoma of the upper respiratory 
tract (1,2). At least 24 of more than 65 genotypes of HPV are 
associated with anogenital lesions and they can be 
subdivided into two groups, the 'low risk' HPVs such as 
HPV6 and HPV11 and the 'high risk' HPVs such as HPV 16 
and HPV 18. HPV DNA has been identified in precancerous 
and neoplastic lesions of the uterine cervix in over 84% of 
patients examined (3). 
At least two early genes, E6 and E7, are consistently 
expressed in HPV-associated cervical cancers and their 
derived cell lines. E6 and E7 genes bind to the cellular p53 
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polymerase chain reaction 
and Rb tumor suppressor proteins, respectively (4-6) and are 
sufficient for in vitro cellular immortalization (7,8). In 
contrast to fully transformed cervical carcinoma cells, HPV-
immortalized keratinocytes are nontumorigenic in nude 
mice (9). 
As is the case for other DNA tumor viruses, the 
development of HPV-associated cancer is presumed to be a 
multistep process. Since HPV 16 and HPV 18 are able to 
immortalize primary keratinocytes, but they are not 
sufficient, except in rare cases, to engender a full tumorigenic 
conversion (10), it has been suggested that activation of 
cellular oncogenes is necessary for the progression of 
cervical cancer. Activation of c-myc and Η-ras appears to be 
quite common in cervical cancers, and overexpression of c-
myc is associated with poor prognosis (11,12). Furthermore, 
it has been demonstrated that a ras gene can induce 
tumorigenic conversion of HPV-immortalized cervical 
keratinocytes (13,14) indicating a cooperative effect between 
the ras and E6/E7 genes in cellular transformation. 
Additionally, the observation that overexpression of 
HPV 18 E6, c-myc or activated Η-ras can partially overcome 
the growth inhibitory effect of wild-type p53 in NIH3T3 
cells, suggests that the cooperation between HPV E6 and 
these cellular oncogenes is necessary to completely 
overcome the anti-oncogenic reaction of p53 in the 
development of these tumors (15). It has also been 
demonstrated that the rapid ubiquitin-dependent degradation 
of p53 through the E6-E6 associated protein complex (E6-
E6-AP) requires additional cellular factors, present only in 
specific tissues or at certain phases during cell growth or 
differentiation (16). 
Alterations in fos expression, which appear to be an 
important facet of epidermal differentiation in vivo, could 
also contribute to the malignant progression of HPV 
immortalized cells (17). 
Activated ras genes by point mutations have been 
reported in cervical cancer, although at low frequency (18), 
while in endometrial carcinomas the frequency was 
significantly higher (18-20). Mutations of K-ras oncogene 
have also been reported in human mucinous ovarian tumors 
(21). 
In the current study the presence of codon 12 point 
mutations of K-, H- and N-ras genes, as well as detection and 
typing of the human papillomavirus was examined in 112 
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N-ras oncogene sequence with wild type codon 12 
5 ' . . . ACAAACTGGTGGTGGTTGGAGCAGGTGGTG ATGAATATGATCCCACCATAGAGGAT. . . 3 ' 
5 ' AACTGGTGGTGGTTGGAGCC. 3' 3'TTATACTAGGGTGGTATCTC 5' 
NA12 primer NB12 primer 
PCR amplification 
Τ 
5 ' AACTGGTGGTGGTTGGAGCCGGTGGTG AATATGATCCCACCATAGAG3 ' 
PCR product (98bp) 
Map I digestion 
Τ 
5' AACTGGTGGTGGTTGGAGC 3' 5 ' CGGTGGTG AATATGATCCCACCATAGAG31 
19bp 79bp 
Digestion products 
Mspl site: C C G G 
Figure 1. N-ras codon 12 PCR-RFLP analysis. The PCR amplification product (98bp) was digested with the restriction endonuclease Mspl. Samples containing 
the normal codon 12 produced a 79 and a 19bp fragment. Samples containing mutant codon 12 (at 1st and 2nd position) remained undigested (98bp). 
cases of genital lesions. Mutationally activated ras genes 
were found in cervical, endometrial and ovarian lesions, with 
the highest incidence occuring in cervical malignant lesions 
(28.2% of K-ras mutations). HPV was found in cervical and 
endometrial lesions, with a higher rate in malignant cervical 
lesions (76.9%). HPV 18 was detected at a higher rate than 
HPV16 (30.2% vs 27.9%) in genital lesions. 
Materials and methods 
Patients and specimens. Tissue specimens were obtained 
from 112 patients with genital lesions, treated at the 
Department of Obstetrics and Gynecology, Medical School, 
University of Crete, Heraklion and the Department of 
Obstetrics and Gynecology, Medical School, University of 
Ioannina, Greece. Hematoxylin-eosin stained sections from 
all paraffin blocks were reviewed to reconfirm the diagnosis, 
the tumor type and differentiation and representative blocks 
(one per case) were selected for further analysis. 
DNA extraction. Five or six 10 μπι thick sections from 
formalin fixed, paraffin-embedded tissues were lysed in 400 
μΐ digestion buffer, containing 100 raM NaCl, 10 mM Tris-
HC1, 25 mM EDTA, 0.5% SDS pH 8.0 and 0.1 mg/ml 
proteinase K. Samples were incubated for 2 h at 60°C. Fresh 
proteinase Κ was added and the incubation was continued for 
another 2 h. The samples were then extracted twice with 
phenol/ chloroform and once with chloroform. DNA was 
precipitated with the addition of 25 μΐ 5 M NaCl and 1 ml 
ethanol, recovered with centrifugation for 15 min at 4°C, 
washed once with cold 70% ethanol and resuspended in 20 μΐ 
double distilled water. 
Oligonucleotide primers and PCR amplification. The 
oligonucleotides used for K-ras and Η-ras codon 12 have 
been previously described (22). For N-ras codon 12 we used 
the oligonucleotides: NA12: 5' AACTGGTGGTGGT 
TGGAGCC 3' and NB12: 5' CTCTATGGTGGGATCA 
TATT 3' (Fig. 1). For the detection and distinction of the 
HPV the general primers GP5 and GP6 (23) and specific 
primers to amplify each virus type HPV11, 16, 18 and 33 
(24) were used. Taq polymerase was purchased from 
Advanced Biotechnology. Two μΐ of the extracted DNA of 
each sample were amplified in a volume of 50 μΐ under the 
following conditions: 
K-ras amplification. The reaction solution contained 10 mM 
Tris-HCl pH 8.3, 50 mM KCl, 3.5 mM MgCl2, 0.01% 
gelatin, 200 μΜ of each dNTP, 1 μΜ of each primer and 
1.25 U Taq polymerase. The mixture was heated for 1 min at 
95°C and then subjected to 40 cycles of amplification. Each 
cycle included a denaturation step at 94°C for 50 sec, an 
annealing step at 58°C for 45 sec and an elongation step at 
72°C for 50 sec, increasing the elongation time 1 sec per 
cycle. 
Η-ras amplification. The reaction solution contained 20 mM 
(NH4)2S04, 2.5 mM MgCl2, 75 mM Tris-HCl pH 9.0, 0.01% 
(w/v) Tween, 200 μΜ of each dNTP, 0.5 μΜ of each primer 
and 1.25 U Taq polymerase. The mixture was heated for 1 
min at 95 °C, and then subjected to 40 cycles of amplification. 
Each cycle included a denaturation step at 94°C for 50 sec, 
an annealing step at 62°C for 40 sec and an elongation step at 
72°C for 50 sec, increasing the elongation time 1 sec per 
cycle. 
N-ras amplification. The reaction solution contained 20 mM 
(NH4)2S04, 2.25 mM MgCl2, 75 mM Tris-HCl pH 9.0, 0.01% 
(w/v) Tween, 200 μΜ of each dNTP, 0.75 μΜ of each primer 
and 1.25 U Taq polymerase. The mixture was heated for 1 
min at 95°C, and then subjected to 40 cycles of amplification. 
Each cycle included a denaturation step at 94°C for 1 min, an 
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annealing step at 58°C for 45 sec and an elongation step at 
72°C for 25 sec, increasing the elongation time 1 sec per 
cycle. 
HPV amplification. The reaction solution, using the general 
primers GP5 and GP6, contained 20 mM (NH4)2S04, 2.5 mM 
MgCl,, 75 mM Tris-HCl pH 9.0, 0.01% (w/v) Tween, 200 
μΜ of each dNTP, 0.75 μΜ of each primer and 1.25 U Taq 
polymerase. The mixture was heated for 1 min at 95°C, and 
then subjected to 40 cycles of amplification. Each cycle 
included a denaturation step at 94°C for 50 sec, an annealing 
step at 52°C for 50 sec and an elongation step at 72°C for 45 
sec, increasing the elongation time 1 sec per cycle. 
Multiplex PCR was employed for the distinction of HPV 
types, where four pairs of primers were used stimultaneously 
(for HPV types 11, 16, 18 and 33), with each virus type giving 
different length of amplified DNA. The reaction solution, 
using the specific set of primers contained 20 mM 
(NH4)2S04, 2.5 mM MgCl,, 75 mM Tris-HCl pH 9.0, 0.01% 
(w/v) Tween, 250 μΜ of each dNTP, 0.5 μΜ of each primer 
and 1.25 U Taq polymerase. The mixture was heated for 1 
min at 95°C, and then subjected to 35 cycles of amplification. 
Each cycle included a denaturation step at 94°C for 1 min, an 
annealing step at 56°C for 50 sec and an elongation step at 
72°C for 50 sec, increasing the elongation time 1 sec per 
cycle. To establish type specificity of primer-directed 
ampification, each set of primers was tested with template 
Plasmid DNA of the five HPV types 6b, 11, 16, 18 and 33. 
RFLP analysis. K-ras: 10-20 μΐ aliquots of the amplification 
products were digested for 3 h with 40 U BstNI. 
H-ras or Ν-ras. 10-20 μΐ aliquots of the amplification 
products were digested O/N with 40 U Mspl. 
Digestion products were electrophoresed through an 8% 
Polyacrylamide gel, or a 4% agarose gel. 
HPV-general primers. The type distinction using the specific 
primers was reconfirmed with digestion of the amplification 
products, using the general primers, with 50 U of Rsal giving 
a different pattern for each type. Digestion products were 
electrophoresed through a 10% Polyacrylamide gel. As 
control the amplified product of plasmid DNA of the HPV 
types 6b, 11, 16, 18 and 33 were used. 
Gels were stained with ethidium bromide and 
photographed on a UV light transilluminator. Enzymes were 
supplied by New England Biolabs and the conditions 
followed for digestions were those recommended by the 
supplier. Incubation temperatures were 60°C for BstNI and 
37°C for Mspl and Rsal. 
Statistical analysis. Statistical analysis was performed on a 
Macintosh computer with the help of STATWORK (version 
1.2) software. 
Results 
After reviewing the selected tissue sections of 112 samples, 
the histological diagnosis, tumor classification and 
differentiation was as follows: There were 37 cases of 
cervicitis, 10 cervical intraepithelial neoplasias (CIN I: 3 
Figure 2. K-ras amplification products (157bp) were digested with the 
restriction endonuclease BstNI and electrophoresed through a 4% agarose 
gel. Lanes 1,2,6: positive samples, lanes 3,4,5,7: negative samples (113bp), 
lane 8: positive control SW480 cell line (142bp), lane 9: undigested PCR 
product, lane M: molecular weight marker pUCI8/HaeIII. 
cases, CIN II: 1 case, CIN II-III: 1 case, CIN III: 5 cases), 7 
cervical adenocarcinomas (well differentiated: 2 cases, 
moderately: 2 cases, poorly: 3 cases), 1 in situ squamous cell 
cervical carcinoma, 29 squamous cell cervical carcinomas 
(well differentiated: 2 cases, moderately: 23 cases, poorly: 4 
cases), 1 undifferentiated clear cell carcinoma, 14 
endometrial adenocarcinomas (well differentiated: 7 cases, 
moderately: 5 cases, poorly: 1 case, Grade IV: 1 case), 1 
poorly differentiated clear cell endometrial carcinoma, 1 
leiomyosarcoma of the uterus, 5 ovarian adenocarcinomas 
(poorly differentiated: 2 cases), 1 moderately differentiated 
serous ovarian cystadenocarcinoma, 1 borderline mucinous 
ovarian tumor, 1 Krukenberg tumor, 2 squamous cell 
carcinomas of the vulva (moderately differentiated: 1 case). 
In the current study we examined the presence of point 
mutations in codon 12 of K-, H- and N-ras genes and 
performed detection and distinction of the human 
papillomavirus in 112 cases of genital lesions. 
Sixteen out of the 112 samples were found to carry a 
point mutation in codon 12 of K-ras (Fig. 2), 9 of H-ras (Fig. 
3), while only 4 of N-ras gene (Fig. 4). Our study was 
limited to codon 12 of the K-ras gene, since mutations 
preferentially occur at this codon (25). The K-ras mutations 
were found in 2 out of 37 (5.4%) patients with cervicitis, in 1 
out of 10 (10%) with CIN II, in 2 out of 7 (28.6%) with well 
differentiated cervical adenocarcinoma, in 1 patient with in 
situ squamous cell carcinoma, in 7 out of 29 (24.1%) with 
squamous cell carcinoma of the cervix (6 cases of moderately 
and 1 case of poorly differentiated), in 1 patient with 
moderately differentiated mucoepidermoid carcinoma of the 
cervix, in 1 out of 14 (7.1%) with a moderately differentiated 
endometrial adenocarcinoma and 1 out of 5 (20%) patients 
with a poorly differentiated ovarian adenocarcinoma. The H-
ras mutations were found in 2 out of 37 (5.4%) patients with 
cervicitis, in 2 out of 10 (20%) with CIN II and CIN III, in 1 
out of 7 (14.3%) with a well differentiated cervical 
adenocarcinoma, in 2 out of 31 (6.5%) with moderately 
differentiated squamous cell cervical carcinoma and in 2 out 
of 14 (14.3%) with moderately differentiated endometrial 
adenocarcinoma. The N-ras mutations were found in 1 out of 
37 (2.7%) patients with cervicitis, in 1 patient of in situ 
squamous cell carcinoma of the cervix and in 2 out of 29 
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M 1 2 3 4 5 6 7 8 9 7 8 9 10111213 M 
bp 
312 
(mt) 291 
(wt) 236 
Figure 3. Η-ras amplification products (312bp) were digested with the 
restriction endonuclease Mspl and electrophoresed through a 4% agarose 
gel. Lane M: molecular weight marker pUCl8/HaeIII, lane 1: undigested 
PCR product, lane 2: positive control EJ cell line (291bp), lanes 3,5,7,8,9 
negative samples, lanes 4,6: positive samples (236bp). 
Figure 6. Type distinction of HPV employing a multiplex PCR. Products of 
different size (315bp: HPV16, 236bp: HPV11, 171bp: HPV33 and 143bp: 
HPV 18) were analysed by agarose gel electrophoresis. Lane M: molecular 
weight marker pUC18/HaeIII, lane 1,13: control plasmids pHPVló. 
pHPVl 1, pHPV33, pHPV18, lane 2,6,7,10,12: samples positive for HPV18, 
lane 3,9: samples positive for HPV16-HPV18, lane 4: sample positive for 
HPV11-HPV18, lane 5: sample positive for HPV16, lane 8: sample positive 
for HPV 16, lane 11: sample positive for HPV33. 
M 1 2 3 4 5 6 7 8 9 1011121314 M 
Figure 4. N-ras amplification products (98bp) were digested with the 
restriction endonuclease Mspl and electrophoresed through a 4% agarose 
gel. Lane M: molecular weight marker pUC18/HaeIII, lanes 1,14: positive 
control undigested PCR product (98bp), lanes 2,3,5,6,7,9,10,11,12,13: 
negative samples, lanes 4,8: positive samples (79bp). 
1 2 3 4 5 6 7 8 9 10 
Figure 5. Type distinction of HPV using the general primers. PCR products 
were digested with the restriction endonuclease Rsal and electrophoresed 
through a 10% Polyacrylamide gel. Lane 1: molecular weight marker 
pUC18/HaeIII, lane 2: undigested PCR product, lane 3: control HPV11 
(109/30bp), lane 4: control HPV16 (30/42/70bp), lane 5: control HPV18 
(30/38/77bp), lane 6: control HPV33 (30/39/70bp), lanes 7,10: samples 
positive for HPV18, lanes 8,9: samples positive for HPV16. 
(6.9%) patients with squamous cell cervical carcinoma (1 case 
well and 1 case moderately differentiated). 
Fifty-eight out of the 112 genital lesions were found 
positive for HPV (Figs. 5 and 6) with the highest incidence 
occuring in squamous cell carcinomas of the cervix (79.3%) 
while in intraepithelial and benign lesions of the cervix, the 
incidence was lower (70.0% and 40.5% respectively, 
p=0.001). The results of PCR analysis of the 112 samples are 
summarized in Table I. 
K-ras mutations and HPV were more frequently found in 
malignant lesions of the cervix (28.2% and 76.9% 
respectively) than in benign (5.4% and 40.5% respectively, 
p<0.008), while in malignant cervical lesions with K-ras 
mutations, HPV was often detected in the same sample 
(25.6% vs 2.7%, p=0.004). The highest incidence of K-ras 
mutations was observed in squamous cell carcinomas of the 
cervix (24.1%), while K-ras mutations also occured in cases 
of cervicitis (5.4%). A comparative analysis between benign 
and malignant lesions of the cervix is shown in Table II,a. 
Results from the type distinction of HPV indicated that 
HPV 18 was the most frequent type (with an incidence of 
30.2%) while HPV 16 was found at a lower rate (27.9%). 
HPV6 was not detected in any lesion, while HPV 11 was 
more prevalent in benign lesions, often as a co-infection with 
HPV 18 (Table II,b). 
Correlation between the presence of ras mutations and 
HPV with the histological differentiation of cervical tumors 
is summarized in Table III. The frequency of ras mutations 
was related to histological differentiation of the tumor, since 
it was higher in well differentiated (50%) than in moderately 
differentiated tumors (8%, p=0.011), although the stage was 
not available for all the tumors. The rate of HPV DNA 
detection was more frequent in patients with poorly 
differentiated (85.7%) than in patients with moderately or 
well differentiated tumors (44% and 33% respectively, 
p<0.059). 
Discussion 
The multi-event nature of carcinogenesis has led to extensive 
studies of oncogenes, onco-suppressor genes and viral factors 
involved in animal and human cancers. The collaboration of 
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Table I. Detection of HPV and mutations of the K-ras, Η-ras and N-ras oncogenes in human genital lesions by PCR-RFLP 
analysis. 
Histological diagnosis Number of 
patients 
HPV 
positive (%) 
Mutations in codon 12 (%) 
K-ras Η-ras N-ras 
Cervix of the uterus 
Cervicitis 
CIN (I, II, III) 
Adenocarcinoma 
In situ squamous cell carcinoma 
Squamous cell carcinoma 
Mucoepidermoid carcinoma 
Clear cell carcinoma 
Corpus of the uterus 
Endometrial adenocarcinoma 
Endometrial clear cell carcinoma 
Leiomyosarcoma of the uterus 
Ovary 
Adenocarcinoma 
Borderline mucinous tumor 
Serous cystadenocarcinoma 
Krukenberg tumor 
Vulva 
Squamous cell carcinoma 
37 
10 
7 
1 
29 
1 
1 
14 
1 
1 
5 
1 
1 
1 
15(40.5) 
7(70) 
5(71.4) 
-
23 (79.3) 
1 
1 
5 
-
-
. 
-
-
. 
2 
1 
2 
1 
7(24.1) 
1 
-
1(7.1) 
-
-
1 
-
-
. 
2 
2 
1 
-
2 
-
-
2 
-
-
_ 
-
-
-
(6.5) 2 (6.9) 
Total 112 58 16 
Table II. a. Comparative study of HPV infection and codon 12 of the ras gene mutations in cervical lesions. 
Types of 
cervical lesions 
Benign 
Premalignant 
Malignant 
Number of 
patients 
37 
10 
39 
HPV 
positive 
(%) 
15 (40.5) 
7(70) 
30 (76.9) 
K-ras 
mutations 
(%) 
2 (5.4) 
1(10) 
11(28.2) 
H-ras 
mutations 
(%) 
2 (5.4) 
2(20) 
3 (7.7) 
N-ras 
mutations 
(%) 
1 (2.7) 
0 
3 (7.7) 
With HPV and 
ras gene 
mutation (%) 
1 (2.7) 
2(20) 
10 (25.6) 
Without HPV 
and ras gene 
mutation (%) 
18 (48.6) 
2(20) 
4(10.3) 
Table II. 
lesions. 
b. Rate of prevalence of HPV type in cervical 
Type of % HPV positive lesions 
HPV Benign Premalignant Malignant Total rate 
HPV-11 
HPV-16 
HPV-18 
HPV-33 
27 
19 
22 
3 
30 
30 
30 
10 
5 
36 
38.5 
10 
17 
27.9 
30.2 
7 
ras oncogene with HPV E6/E7 genes in inducing full 
transformation of cervical keratinocytes has been well 
documented (13,14). However the exact role of the ras 
oncogene in human carcinogenesis is not yet clear, despite 
the fact that ras mutations occur with variable frequency in a 
wide variety of tumors (26). Previous studies have shown 
that the incidence of ras mutations in cervical carcinomas is 
low (11,18). 
The frequency found in the current study for K-ras 
mutations was significantly higher in malignant cervical 
lesions (28.2%) than in benign precursors (5.4%, p=0.008). 
The frequency of ras mutations was higher in well than in 
moderately differentiated tumors, while no mutations were 
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Table III. Analysis of the 39 samples with malignant cervical lesions. 
Histological 
differentiation 
Well differentiated 
Moderately differentiated 
Poorly differentiated 
Undifferentiated 
Total number 
of cases 
6 
25 
7 
1 
"1 sample carries point mutations in codon 12 of both Κ 
Presence of Presence of 
HPV (%) ras mutation 
(%) 
2 (33) 3 (50)a 
11 (44) 2 (8) 
6(85.7) 0 
1 0 
-ras and Η-ras genes. 
Presence of ras 
mutation and 
HPV (%) 
1 (16.7) 
9(36) 
0 
0 
Absence of ras 
mutation and 
HPV (%) 
0 
3(12) 
1 (14.3) 
0 
found in poorly differentiated tumors. The relatively high 
incidence of ras mutations in patients with chronic cervicitis, 
clinically considered as benign lesion, is also of great 
interest. A future report on the clinical follow-up will help to 
elucidate its significance as a prognostic factor. The 
appearance of ras mutations in benign and premalignant 
lesions may contribute to their transition to more advanced 
lesions. This indicates a possible role of ras mutations in the 
initial stages of cervical carcinogenesis. 
In endometrial adenocarcinomas the frequency of all ras 
gene mutations (21.4%) concurred with previous 
observations (18-20). Although there are reports on codon 12 
point mutations of K-ras, none exists in Η-ras gene. 
Variations in the prevalence of HPV types in cervical 
lesions have been found and attributed to geographical 
differences, focal heterogeneity of HPV replication within 
lesions sampled, or variability in the sensitivity of the assays 
employed (24). In areas with high-incidence of cervical 
cancer there seems to be little difference in the prevalence of 
HPV 16 and HPV 18, whereas in areas with moderately-high 
incidence, HPV 16 is more common than HPV 18 (27). In the 
current study we found a higher rate of infection by HPV 18 
(30.2%) compared to HPV 16 (27.9%) in the 86 cervical 
lesions examined. HPV 18 infection was more commonly 
associated with poorer histological differentiation and our 
results are substantiated with previous observations that 
HPV 18 confers greater aggression than HPV 16 and has been 
associated with a more rapid progression to malignancy (28). 
In addition in vivo and in vitro studies have often indicated 
that HPV 18 is more effective in immortalization and 
transformation than HPV 16 (29). 
The simultaneous presence of ras mutations and high risk 
HPV DNA was detected in 10 cases. Its significance is not 
known, but it has been shown that in vitro E6-E7 
immortalized primary human epidermal keratinocytes can be 
rendered malignant after additional transfection with v-ras 
oncogene, while W-ras can overcome the anti-proliferative 
and anti-transformation effects of wild-type p53 in NIH3T3 
cells (13-15). Since the simultaneous presence of HPV and 
K-ras mutations was more frequently detected in malignant 
cervical lesions (25.6%) than in benign (2.7%, p=0.004), a 
cooperation between them in neoplastic change is suggested. 
These experiments support a multistep process for 
malignant conversion, since for tumors that do not contain 
any detectable ras mutation alternative genetic alterations are 
presumed. The availability of human epithelial cell 
transformation model should facilitate studies of the 
interaction between HPV and human epithelial cells, ras 
activation combined with HPV infection may be an 
important step in substantial numbers of cervical carcinomas, 
while their interaction with other genes or events may also be 
involved. 
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